10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Xponance Inc.

Xponance Inc. decreased its holdings in 10x Genomics, Inc. (NASDAQ:TXG) by 7.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 12,115 shares of the company’s stock after selling 945 shares during the quarter. Xponance Inc.’s holdings in 10x Genomics were worth $678,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of TXG. Commonwealth Equity Services LLC lifted its stake in shares of 10x Genomics by 26.0% in the third quarter. Commonwealth Equity Services LLC now owns 7,193 shares of the company’s stock worth $297,000 after acquiring an additional 1,486 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in 10x Genomics by 13.9% in the third quarter. Bank of New York Mellon Corp now owns 1,010,256 shares of the company’s stock valued at $41,673,000 after buying an additional 122,981 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in 10x Genomics by 13.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,777 shares of the company’s stock valued at $857,000 after buying an additional 2,419 shares during the last quarter. Strs Ohio increased its holdings in 10x Genomics by 16.8% in the third quarter. Strs Ohio now owns 13,789 shares of the company’s stock valued at $568,000 after buying an additional 1,986 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in 10x Genomics by 10.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 167,494 shares of the company’s stock valued at $6,909,000 after buying an additional 15,256 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company’s stock.

10x Genomics Trading Up 2.6 %

Shares of 10x Genomics stock opened at $27.59 on Friday. The business’s 50 day simple moving average is $37.70 and its 200-day simple moving average is $42.52. 10x Genomics, Inc. has a twelve month low of $26.30 and a twelve month high of $63.57.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings results on Thursday, February 15th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.05). The company had revenue of $183.98 million for the quarter, compared to analyst estimates of $182.73 million. 10x Genomics had a negative return on equity of 28.82% and a negative net margin of 41.17%. The firm’s revenue for the quarter was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.15) earnings per share. Research analysts anticipate that 10x Genomics, Inc. will post -1.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft lowered their price objective on 10x Genomics from $60.00 to $55.00 and set a “buy” rating for the company in a report on Thursday, April 18th. Stifel Nicolaus lowered their price objective on 10x Genomics from $68.00 to $63.00 and set a “buy” rating for the company in a report on Friday, February 16th. Finally, Barclays lowered their price objective on 10x Genomics from $55.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, April 10th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $60.22.

Insider Activity at 10x Genomics

In related news, CEO Serge Saxonov sold 4,660 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $44.00, for a total value of $205,040.00. Following the sale, the chief executive officer now directly owns 842,900 shares in the company, valued at approximately $37,087,600. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CFO Justin J. Mcanear sold 1,865 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total value of $86,424.10. Following the sale, the chief financial officer now directly owns 95,240 shares in the company, valued at approximately $4,413,421.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Serge Saxonov sold 4,660 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $44.00, for a total value of $205,040.00. Following the completion of the sale, the chief executive officer now owns 842,900 shares in the company, valued at $37,087,600. The disclosure for this sale can be found here. Insiders have sold a total of 12,959 shares of company stock worth $592,806 in the last three months. 10.65% of the stock is owned by company insiders.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.